Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized placebo-controlled study of RXC007 in idiopathic pulmonary fibrosis
2022-000498-15Phase 2Completed
- Sponsor
- Redx Pharma
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zelasudil in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Redx Pharma. Primary endpoint: Safety and tolerability of RXC007. Started Jun 2022; status: completed.
02
Drugs
zelasudil
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2022-000498-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000498-15.